secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001193125-23-200540
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 3.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences raises $25M in private placement; announces promising FB-102 data in GvHD
--------------------------------------------------------------------------------

- Raised ~$25M gross from private placement with top-tier institutional investors; execs and board purchased $1.16M.
- FB-102 (anti-CD122) showed 90% survival in acute GvHD model vs 0% vehicle, superior to ruxolitinib (60% single agent).
- Combination of FB-102 with ruxolitinib yielded 90% survival vs 30% for ruxolitinib alone in preclinical model.
- Forte plans to advance FB-102 into clinic in 2024; preclinical PoC data supports potential in vitiligo, celiac, alopecia, T1D, and transplant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312523200540/0001193125-23-200540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312523200540/d470879d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-200540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer